Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study

• Egile Nagusiak: Paul Martin (Egilea), Sarah Gleeson (Egilea), Candice L. Clarke (Egilea), Tina Thomson (Egilea), Helena Edwards (Egilea), Katrina Spensley (Egilea), Paige Mortimer (Egilea), Stacey McIntyre (Egilea), Alison Cox (Egilea), Graham Pickard (Egilea), Liz Lightstone (Egilea), David Thomas (Egilea), Stephen P. McAdoo (Egilea), Peter Kelleher (Egilea), Maria Prendecki (Egilea), Michelle Willicombe (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: People with end-stage kidney disease, including people on haemodialysis, are susceptible to greater COVID-19 related morbidity and mortality. This study compares the immunogenicity and clinical effectiveness of BNT162B2 versus ChAdOx1 in haemodialysis patients. Methods: In this...